Utility of SPM8 plus DARTEL (VSRAD) combined with magnetic resonance spectroscopy as adjunct techniques for screening and predicting dementia due to Alzheimer's disease in clinical practice

Journal of Alzheimer's Disease

Volumn 41, Issue 4, 2014, Pages 1207-1222

  Waragai, Masaaki ^a   Hata, Saori ^b   Suzuki, Toshiharu ^b   Ishii, Ryotaro ^c   Fujii, Chihiro ^c   Tokuda, Takahiko ^c   Arai, Hiroyuki ^d   Ohrui, Takashi ^d   Higuchi, Susumu ^e   Yoshida, Madoka ^f   Igarashi, Kazuei ^f   Moriya, Masaru ^a   Iwai, Naomichi ^a   Uemura, Kenichi ^a  

^a Higashi Matsudo City Hospital   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

^e KURIHAMA NATIONAL HOSPITAL   (Japan)

^f CHIBA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; magnetic resonance imaging; magnetic resonance spectroscopy (1H MRS); screening; SPM8 plus DARTEL (VSRAD); surrogate marker

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; BREAST ATROPHY; CEREBROSPINAL FLUID; CLINICAL PRACTICE; COMPUTER PROGRAM; CONTROLLED STUDY; DARTEL; DATA ANALYSIS SOFTWARE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; NORMOTENSIVE HYDROCEPHALUS; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCREENING TEST; VALIDATION STUDY; ANALOGS AND DERIVATIVES; BRAIN; COMPLICATION; DIAGNOSTIC USE; DISEASE COURSE; LONGITUDINAL STUDY; MALE; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA-PROTEIN (1-42); ASPARTIC ACID; CHOLINE; N-ACETYLASPARTATE; PEPTIDE FRAGMENT; TRITIUM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ASPARTIC ACID; BRAIN; CHOLINE; DEMENTIA; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; TRITIUM;

EID: 84908170463     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132786     Document Type: Article

References (58)

1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
2. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, BucklesV, OliverA,Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804.
3. Lin JS, O'Connor E, Rossom RC, Perdue LA, Eckstrom E (2013) Screening for cognitive impairment in older adults: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 159, 601-612.
4. Lista S, Garaci FG, Ewers M, Teipel S, ZetterbergH, Blennow K, HampelH(2014) CSFAβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. Alzheimers Dement 10, 381-392.
5. Kandimalla RJ, Prabhakar S,WaniWY, Kaushal A, Gupta N, Sharma DR, Grover VK, Bhardwaj N, Jain K, Gill KD (2013) CSF p-Tau levels in the prediction of Alzheimer's disease. Biol Open 2, 1119-1124.
6. Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC (2013) CSF biomarkers of Alzheimer disease: "Noncognitive" outcomes. Neurology 81, 2028-2031.
7. Moghekar A, Li S, Lu Y, Li M,Wang MC, Albert M, O'Brien R (2013) CSF biomarker changes precede symptom onset of mild cognitive impairment. Neurology 81, 1753-1758.
8. Ashburner J, Friston KJ (2000) Voxel-based morphometry-the methods. Neuroimage 11, 805-821.
9. Hirata Y, Matsuda H, Nemoto K, Ohnishi T, Hirao K, Yamashita F, Asada T, Iwabuchi S, SamejimaH (2005) Voxel based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 382, 269-274.
10. Hayashi H, Kawakatsu S, Suzuki A, Shibuya Y, Kobayashi R, Sato C, Otani K (2012) Application of the VSRAD, a specific and sensitive voxel-based morphometry, to comparison of entorhinal cortex atrophy between dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cogn Disord 34, 328-331.
11. Matsuda H, Mizumura S, Nemoto K,Yamashita F, Imabayashi E, Sato N, Asada T (2012) Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer disease. AJNR Am J Neuroradiol 33, 1109-1114.
12. Kantarci K, Ferman TJ, Boeve BF, Weigand SD, Przybelski S, Vemuri P, Murray ME, Senjem ML, Smith GE, Knopman DS, Petersen RC, Jack CR, Jr., Parisi JE, Dickson DW(2012) Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology 79, 553-560.
13. Nakatsuka T, Imabayashi E, Matsuda H, Sakakibara R, Inaoka T, Terada H (2013) Discrimination of dementia with Lewy bodies from Alzheimer's disease using voxel-based morphometry of white matter by statistical parametric mapping 8 plus diffeomorphic anatomic registration through exponentiated Lie algebra. Neuroradiology 55, 559-566.
14. Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, Knopman DS, Petersen RC, Benarroch EE, Josephs KA, Jack CR, Jr. (2007) Focal atrophy in dementia with Lewy bodies on MRI: A distinct pattern from Alzheimer's disease. Brain 130, 708-719.
15. Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, Vemuri P, Senjem ML, Parisi JE, Knopman DS, Boeve BF, Petersen RC, DicksonDW, Jack CR, Jr. (2008) MRI correlates of neurofibrillary tangle pathology at autopsy: A voxel-based morphometry study. Neurology 71, 743-749.
16. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, KudoY, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, HiguchiM(2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094-1108.
17. Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, Mulligan RS, Villemagne VL, Akatsu H, Yamamoto T, Arai H, Iwata R, Yanai K, Kudo Y (2013) Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 54, 1420-1427.
18. Chien DT, Szardenings AK, Bahri S,Walsh JC, Mu F, Xia C, Shankle WR, Lerner AJ, SuMY, Elizarov A, Kolb HC (2014) Early clinical PET Imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis 38, 171-184.
19. Kantarci K, Weigand SD, Przybelski SA, Preboske GM, Pankratz VS, Vemuri P, Senjem ML, Murphy MC, Gunter JL, Machulda MM, Ivnik RJ, Roberts RO, Boeve BF, Rocca WA, Knopman DS, Petersen RC, Jack CR, Jr. (2013) MRI and MRSpredictors of mild cognitive impairment in a populationbased sample. Neurology 81, 118-133.
20. Kantarci K (2013) Proton MRS in mild cognitive impairment. J Magn Reson Imaging 37, 770-777.
21. Gasparovic C, Prestopnik J, Thompson J, Taheri S, Huisa B, Schrader R, Adair JC, Rosenberg GA (2013) 1 H-MR spectroscopy metabolite levels correlate with executive function in vascular cognitive impairment. J Neurol Neurosurg Psychiatry 84, 715-721.
22. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, Josephs KA, Boeve BF, Petersen RC, Jack CR, Jr. (2008) Alzheimer disease: Postmortem neuropathologic correlates of antemortem 1 H MR spectroscopy metabolite measurements. Radiology 248, 210-220.
23. Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL, Negash S, Knopman DS, Boeve BF, O'Brien PC, Petersen RC, Jack CR, Jr. (2009) Risk of dementia in MCI: Combined effect of cerebrovascular disease, volumetric MRI, and 1 H MRS. Neurology 72, 1519-1525.
24. Kantarci K, Petersen RC, Przybelski SA,Weigand SD, Shiung MM, Whitwell JL, Negash S, Ivnik RJ, Boeve BF, Knopman DS, Smith GE, Jack CR, Jr. (2008) Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol 65, 1621-1628.
25. Wang L, Brier MR, Snyder AZ, Thomas JB, Fagan AM, Xiong C, Benzinger TL, HoltzmanDM,Morris JC, AncesBM (2013) Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. JAMA Neurol 70, 1242-1248.
26. Westman E, Wahlund LO, Foy C, Poppe M, Cooper A, Murphy D, Spenger C, Lovestone S, Simmons A (2011) Magnetic resonance imaging and magnetic resonance spectroscopy for detection of early Alzheimer's disease. J Alzheimers Dis 26, 307-319.
27. Modrego PJ, Fayed N (2011) Longitudinal magnetic resonance spectroscopy as marker of cognitive deterioration in mild cognitive impairment. Am J Alzheimers Dis Other Demen 26, 631-636.
28. Metastasio A, Rinaldi P, Tarducci R, Mariani E, Feliziani FT, Cherubini A, Pelliccioli GP, Gobbi G, Senin U, Mecocci P (2006) Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy. Neurobiol Aging 27, 926-932.
29. Modrego PJ, Fayed N, Pina MA (2005) Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 162, 667-675.
30. Jessen F, Traeber F, Freymann K, MaierW, Schild HH, Block W(2006) Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 67, 528-530.
31. Kantarci K (2007) 1 H magnetic resonance spectroscopy in dementia. Br J Radiol 80, S146-S152.
32. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, Gunter J, Reyes D, Shiung M, O'Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Jack CR, Jr. (2007) Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 28, 1330-1339.
33. Diaz-de-Grenu LZ, Acosta-Cabronero J, Chong YF, Pereira JM, Sajjadi SA,Williams GB, Nestor PJ (2014)Abrief history of voxel-based grey matter analysis in Alzheimer's disease. J Alzheimers Dis 38, 647-659.
34. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
35. McKeith IG, DicksonDW,Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872.
36. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
37. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308.
38. PetersenRC(2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
39. Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K, YamadaM(2006) Value of 123IMIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 66, 1850-1854.
40. Kantarci K, Jack CR, Jr., Xu YC, Campeau NG, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokmen E, Tangalos EG, Petersen RC (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1 H MRS study. Neurology 55, 210-217.
41. Kantarci K, Xu Y, Shiung MM, O'Brien PC, Cha RH, Smith GE, Ivnik RJ, BoeveBF, Edland SD,Kokmen E,Tangalos EG, Petersen RC, Jack CR, Jr. (2002) Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 14, 198-207.
42. Gasparovic C, Prestopnik J, Thompson J, Taheri S, Huisa B, Schrader R, Adair JC, Rosenberg GA (2013) 1 H-MR spectroscopy metabolite levels correlate with executive function in vascular cognitive impairment. J Neurol Neurosurg Psychiatry 84, 715-721.
43. Westman E, Wahlund LO, Foy C, Poppe M, Cooper A, Murphy D, Spenger C, Lovestone S, Simmons A (2011) Magnetic resonance imaging and magnetic resonance spectroscopy for detection of early Alzheimer's disease. J Alzheimers Dis 26, 307-319.
44. Metastasio A, Rinaldi P, Tarducci R, Mariani E, Feliziani FT, Cherubini A, Pelliccioli GP, Gobbi G, Senin U, Mecocci P (2006) Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy. Neurobiol Aging 27, 926-932.
45. Kantarci K, Reynolds G, Petersen RC, Boeve BF, Knopman DS, Edland SD, Smith GE, Ivnik RJ, Tangalos EG, Jack CR, Jr. (2003) Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: Comparison of 1.5 and 3 T. AJNR Am J Neuroradiol 24, 843-849.
46. Kantarci K, Lowe V, Przybelski SA, Senjem ML, Weigand SD, Ivnik RJ, Roberts R, Geda YE, Boeve BF, Knopman DS, Petersen RC, Jack CR, Jr. (2011) Magnetic resonance spectroscopy, β-amyloid load, and cognition in a populationbased sample of cognitively normal older adults. Neurology 77, 951-958.
47. Godbolt AK,Waldman AD, MacManus DG, Schott JM, Frost C, Cipolotti L, Fox NC, Rossor MN (2006) MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology 66, 718-722.
48. Kantarci K, Boeve BF,Wszolek ZK, Rademakers R, Whitwell JL, Baker MC, Senjem ML, Samikoglu AR, Knopman DS, Petersen RC, Jack CR, Jr. (2010) MRS in presymptomatic MAPT mutation carriers: A potential biomarker for taumediated pathology. Neurology 75, 771-778.
49. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O'Brien PC, Weigand SD, Edland SD, Smith GE, Ivnik RJ, Ferman TJ, Tangalos EG, Jack CR, Jr. (2004) 1HMRspectroscopy in common dementias. Neurology 63, 1393-1398.
50. Watanabe T, Shiino A, Akiguchi I (2008) Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease. Dement Geriatr Cogn Disord 26, 89-100.
51. Watanabe T, Shiino A, Akiguchi I (2010) Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer's disease and healthy aging. Dement Geriatr Cogn Disord 30, 71-77.
52. WechlslerD(1987) Wechsler memory scale-revised. The Psychological Corporation, New York.
53. SugishitaM(2001) JapaneseWechsler memory scale-revised [in Japanese], Nihon Bunka Kagakusha, Tokyo.
54. Watanabe T, Shiino A, Akiguchi I (2012) Hippocampal metabolites and memory performances in patients with amnestic mild cognitive impairment and Alzheimer's disease. Neurobiol Learn Mem 97, 289-293.
55. Kreis R, Ernst T, Ross BD (1993) Development of the human brain: In vivo quantification of metabolite and water content with proton magnetic resonance spectroscopy. Magn Reson Med 30, 424-437.
56. Alger JR (2010) Quantitative proton magnetic resonance spectroscopy and spectroscopic imaging of the brain:Adidactic review. Top Magn Reson Imaging 21, 115-128.
57. Li BS,Wang H, GonenO(2003) Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn Reson Imaging 21, 923-928.
58. Tumati S, Martens S, Aleman A (2013) Magnetic resonance spectroscopy in mild cognitive impairment: Systematic review and meta-analysis. Neurosci Biobehav Rev 37, 2571-2586.